ThermoGenesis Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 12, 2022 at 12:52 am IST
Share
ThermoGenesis Holdings, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 3.03 million compared to USD 2.2 million a year ago. Net loss was USD 2.69 million compared to USD 4.54 million a year ago. Basic loss per share from continuing operations was USD 9 compared to USD 17.1 a year ago.
For the six months, sales was USD 5.69 million compared to USD 3.72 million a year ago. Net loss was USD 4.6 million compared to USD 6.95 million a year ago. Basic loss per share from continuing operations was USD 16.2 compared to USD 26.55 a year ago.
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.